RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer Read more
Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com Read more